table of content
1 Introduction to Research & Analysis Reports
1.1 Viral Vectors Gene Therapy Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Viral Vectors Gene Therapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Viral Vectors Gene Therapy Overall Market Size
2.1 Global Viral Vectors Gene Therapy Market Size: 2022 VS 2029
2.2 Global Viral Vectors Gene Therapy Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Viral Vectors Gene Therapy Players in Global Market
3.2 Top Global Viral Vectors Gene Therapy Companies Ranked by Revenue
3.3 Global Viral Vectors Gene Therapy Revenue by Companies
3.4 Top 3 and Top 5 Viral Vectors Gene Therapy Companies in Global Market, by Revenue in 2022
3.5 Global Companies Viral Vectors Gene Therapy Product Type
3.6 Tier 1, Tier 2 and Tier 3 Viral Vectors Gene Therapy Players in Global Market
3.6.1 List of Global Tier 1 Viral Vectors Gene Therapy Companies
3.6.2 List of Global Tier 2 and Tier 3 Viral Vectors Gene Therapy Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Viral Vectors Gene Therapy Market Size Markets, 2022 & 2029
4.1.2 Retro Viral Vectors
4.1.3 Adeno-associated Virus Vectors
4.1.4 Other Viral Vectors
4.2 By Type - Global Viral Vectors Gene Therapy Revenue & Forecasts
4.2.1 By Type - Global Viral Vectors Gene Therapy Revenue, 2018-2023
4.2.2 By Type - Global Viral Vectors Gene Therapy Revenue, 2024-2029
4.2.3 By Type - Global Viral Vectors Gene Therapy Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Viral Vectors Gene Therapy Market Size, 2022 & 2029
5.1.2 In Vivo
5.1.3 Ex Vivo
5.2 By Application - Global Viral Vectors Gene Therapy Revenue & Forecasts
5.2.1 By Application - Global Viral Vectors Gene Therapy Revenue, 2018-2023
5.2.2 By Application - Global Viral Vectors Gene Therapy Revenue, 2024-2029
5.2.3 By Application - Global Viral Vectors Gene Therapy Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region - Global Viral Vectors Gene Therapy Market Size, 2022 & 2029
6.2 By Region - Global Viral Vectors Gene Therapy Revenue & Forecasts
6.2.1 By Region - Global Viral Vectors Gene Therapy Revenue, 2018-2023
6.2.2 By Region - Global Viral Vectors Gene Therapy Revenue, 2024-2029
6.2.3 By Region - Global Viral Vectors Gene Therapy Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country - North America Viral Vectors Gene Therapy Revenue, 2018-2029
6.3.2 US Viral Vectors Gene Therapy Market Size, 2018-2029
6.3.3 Canada Viral Vectors Gene Therapy Market Size, 2018-2029
6.3.4 Mexico Viral Vectors Gene Therapy Market Size, 2018-2029
6.4 Europe
6.4.1 By Country - Europe Viral Vectors Gene Therapy Revenue, 2018-2029
6.4.2 Germany Viral Vectors Gene Therapy Market Size, 2018-2029
6.4.3 France Viral Vectors Gene Therapy Market Size, 2018-2029
6.4.4 U.K. Viral Vectors Gene Therapy Market Size, 2018-2029
6.4.5 Italy Viral Vectors Gene Therapy Market Size, 2018-2029
6.4.6 Russia Viral Vectors Gene Therapy Market Size, 2018-2029
6.4.7 Nordic Countries Viral Vectors Gene Therapy Market Size, 2018-2029
6.4.8 Benelux Viral Vectors Gene Therapy Market Size, 2018-2029
6.5 Asia
6.5.1 By Region - Asia Viral Vectors Gene Therapy Revenue, 2018-2029
6.5.2 China Viral Vectors Gene Therapy Market Size, 2018-2029
6.5.3 Japan Viral Vectors Gene Therapy Market Size, 2018-2029
6.5.4 South Korea Viral Vectors Gene Therapy Market Size, 2018-2029
6.5.5 Southeast Asia Viral Vectors Gene Therapy Market Size, 2018-2029
6.5.6 India Viral Vectors Gene Therapy Market Size, 2018-2029
6.6 South America
6.6.1 By Country - South America Viral Vectors Gene Therapy Revenue, 2018-2029
6.6.2 Brazil Viral Vectors Gene Therapy Market Size, 2018-2029
6.6.3 Argentina Viral Vectors Gene Therapy Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Viral Vectors Gene Therapy Revenue, 2018-2029
6.7.2 Turkey Viral Vectors Gene Therapy Market Size, 2018-2029
6.7.3 Israel Viral Vectors Gene Therapy Market Size, 2018-2029
6.7.4 Saudi Arabia Viral Vectors Gene Therapy Market Size, 2018-2029
6.7.5 UAE Viral Vectors Gene Therapy Market Size, 2018-2029
7 Viral Vectors Gene Therapy Companies Profiles
7.1 Amgen
7.1.1 Amgen Company Summary
7.1.2 Amgen Business Overview
7.1.3 Amgen Viral Vectors Gene Therapy Major Product Offerings
7.1.4 Amgen Viral Vectors Gene Therapy Revenue in Global Market (2018-2023)
7.1.5 Amgen Key News & Latest Developments
7.2 Novartis
7.2.1 Novartis Company Summary
7.2.2 Novartis Business Overview
7.2.3 Novartis Viral Vectors Gene Therapy Major Product Offerings
7.2.4 Novartis Viral Vectors Gene Therapy Revenue in Global Market (2018-2023)
7.2.5 Novartis Key News & Latest Developments
7.3 Orchard Therapeutics
7.3.1 Orchard Therapeutics Company Summary
7.3.2 Orchard Therapeutics Business Overview
7.3.3 Orchard Therapeutics Viral Vectors Gene Therapy Major Product Offerings
7.3.4 Orchard Therapeutics Viral Vectors Gene Therapy Revenue in Global Market (2018-2023)
7.3.5 Orchard Therapeutics Key News & Latest Developments
7.4 Spark Therapeutics
7.4.1 Spark Therapeutics Company Summary
7.4.2 Spark Therapeutics Business Overview
7.4.3 Spark Therapeutics Viral Vectors Gene Therapy Major Product Offerings
7.4.4 Spark Therapeutics Viral Vectors Gene Therapy Revenue in Global Market (2018-2023)
7.4.5 Spark Therapeutics Key News & Latest Developments
7.5 Agc Biologics
7.5.1 Agc Biologics Company Summary
7.5.2 Agc Biologics Business Overview
7.5.3 Agc Biologics Viral Vectors Gene Therapy Major Product Offerings
7.5.4 Agc Biologics Viral Vectors Gene Therapy Revenue in Global Market (2018-2023)
7.5.5 Agc Biologics Key News & Latest Developments
7.6 Anges
7.6.1 Anges Company Summary
7.6.2 Anges Business Overview
7.6.3 Anges Viral Vectors Gene Therapy Major Product Offerings
7.6.4 Anges Viral Vectors Gene Therapy Revenue in Global Market (2018-2023)
7.6.5 Anges Key News & Latest Developments
7.7 Bluebird Bio
7.7.1 Bluebird Bio Company Summary
7.7.2 Bluebird Bio Business Overview
7.7.3 Bluebird Bio Viral Vectors Gene Therapy Major Product Offerings
7.7.4 Bluebird Bio Viral Vectors Gene Therapy Revenue in Global Market (2018-2023)
7.7.5 Bluebird Bio Key News & Latest Developments
7.8 Jazz Pharmaceuticals
7.8.1 Jazz Pharmaceuticals Company Summary
7.8.2 Jazz Pharmaceuticals Business Overview
7.8.3 Jazz Pharmaceuticals Viral Vectors Gene Therapy Major Product Offerings
7.8.4 Jazz Pharmaceuticals Viral Vectors Gene Therapy Revenue in Global Market (2018-2023)
7.8.5 Jazz Pharmaceuticals Key News & Latest Developments
7.9 Dynavax Technologies
7.9.1 Dynavax Technologies Company Summary
7.9.2 Dynavax Technologies Business Overview
7.9.3 Dynavax Technologies Viral Vectors Gene Therapy Major Product Offerings
7.9.4 Dynavax Technologies Viral Vectors Gene Therapy Revenue in Global Market (2018-2023)
7.9.5 Dynavax Technologies Key News & Latest Developments
7.10 Biogen
7.10.1 Biogen Company Summary
7.10.2 Biogen Business Overview
7.10.3 Biogen Viral Vectors Gene Therapy Major Product Offerings
7.10.4 Biogen Viral Vectors Gene Therapy Revenue in Global Market (2018-2023)
7.10.5 Biogen Key News & Latest Developments
7.11 Sarepta Therapeutics
7.11.1 Sarepta Therapeutics Company Summary
7.11.2 Sarepta Therapeutics Business Overview
7.11.3 Sarepta Therapeutics Viral Vectors Gene Therapy Major Product Offerings
7.11.4 Sarepta Therapeutics Viral Vectors Gene Therapy Revenue in Global Market (2018-2023)
7.11.5 Sarepta Therapeutics Key News & Latest Developments
7.12 Gilead Sciences
7.12.1 Gilead Sciences Company Summary
7.12.2 Gilead Sciences Business Overview
7.12.3 Gilead Sciences Viral Vectors Gene Therapy Major Product Offerings
7.12.4 Gilead Sciences Viral Vectors Gene Therapy Revenue in Global Market (2018-2023)
7.12.5 Gilead Sciences Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
